An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

659

Participants

Timeline

Start Date

October 30, 2012

Primary Completion Date

November 12, 2024

Study Completion Date

November 12, 2024

Conditions
Hepatocellular Carcinoma
Interventions
BIOLOGICAL

Nivolumab

DRUG

Sorafenib

DRUG

Ipilimumab

DRUG

Cabozantinib

Trial Locations (60)

0

Local Institution - 0005, Hong Kong

100

Local Institution - 0027, Taipei

112

Local Institution - 0024, Taipei

333

Local Institution - 0023, Taoyuan District

13273

Local Institution - 0062, Marseille

13385

Local Institution - 0059, Marseille

20007

Local Institution - 0048, Washington D.C.

20089

Local Institution - 0040, Rozzano

20141

Local Institution - 0055, Milan

28009

Local Institution - 0020, Madrid

28050

Local Institution - 0018, Madrid

30322

Local Institution - 0047, Atlanta

30625

Local Institution - 0029, Hanover

31008

Local Institution - 0003, Pamplona

32504

Local Institution - 0053, Pensacola

40138

Local Institution - 0032, Bologna

45147

Local Institution - 0030, Essen

47014

Local Institution - 0063, Meldola (FC)

49933

Local Institution - 0061, Angers

50134

Local Institution - 0056, Florence

51092

Local Institution - 0060, Reims

54500

Local Institution - 0058, Vandœuvre-lès-Nancy

60590

Local Institution - 0028, Frankfurt

69120

Local Institution - 0031, Heidelberg

75651

Local Institution - 0042, Paris

77030

The University Of Texas MD Anderson Cancer Center, Houston

80131

Local Institution - 0034, Napoli

90033

Local Institution - 0008, Los Angeles

94010

Local Institution - 0064, Créteil

97213

Local Institution - 0001, Portland

119074

Local Institution - 0017, Singapore

168583

Local Institution - 0009, Singapore

308433

Local Institution - 0007, Singapore

2320024

Local Institution - 0049, Yokohama

2778577

Local Institution - 0036, Kashiwa-shi

5898511

Local Institution - 0037, Ōsaka-sayama

6028566

Local Institution - 0050, Kyoto

8300011

Local Institution - 0038, Kurume-shi

8408571

Local Institution - 0051, Saga

02114

Local Institution - 0025, Boston

48109-5331

Local Institution - 0002, Ann Arbor

07601

Local Institution - 0054, Hackensack

07503

Local Institution - 0067, Paterson

B4H 2Y9

Local Institution - 0065, Halifax

M5G 2M9

Local Institution - 0039, Toronto

H2X 3E4

Local Institution - 0022, Montreal

Unknown

Local Institution - 0006, Hong Kong

Padova

Local Institution - 0035, Padua

00927

Local Institution - 0070, San Juan

02841

Local Institution - 0066, Seoul

03080

Local Institution - 0021, Seoul

05505

Local Institution - 0026, Seoul

06351

Local Institution - 0016, Seoul

08036

Local Institution - 0019, Barcelona

SE19RT

Local Institution - 0011, London

M20 4BX

Local Institution - 0014, Manchester

G12 0YN

Local Institution - 0012, Glasgow

CH63 4JY

Local Institution - 0015, Metropolitan Borough of Wirral

B15 2TH

Local Institution - 0013, Birmingham

NW3 2QG

Local Institution - 0010, London

Sponsors
All Listed Sponsors
collaborator

Ono Pharmaceutical Co. Ltd

INDUSTRY

lead

Bristol-Myers Squibb

INDUSTRY